**Andersen-Tawil Syndrome presenting with complete heart block**

Karen Suetterlina, Roope Männikköa, Enrico Flossmannb, Richa Sudc, Doreen Fialhoa, Vino Vivekanandama, Natalie Jamesa, Thomas D Gossiosd, Michael G Hannaa, Kostas Savvatisd, and Emma Matthews,a,e

aQueen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, and Department of Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, WC1N 3BG, London, UK

bRoyal Berkshire Hospital Reading and Nuffield Department of Clinical Neurosciences, University of Oxford, UK

cNeurogenetics Unit, Institute of Neurology, Queen Square, London, UK

dInherited Cardiovascular Diseases Unit, Barts Heart Centre, Barts Healthcare NHS Trust, EC1A 7BE, London, UK

eAtkinson Morley Neuromuscular Centre, Department of Neurology, St George's University Hospitals NHS Foundation Trust, SW17 0QT, London, UK

Corresponding Author: Emma Matthews Email: emma.matthews8@nhs.net

Atkinson Morley Neuromuscular Centre, Department of Neurology, St George's University Hospitals NHS Foundation Trust, SW17 0QT, London, UK

Tel: 0203 108 7513 Fax: 020 3448 3633

**Manuscript:** 785 words **Title:** 60 characters

**References:** 7 **Figures:** 1

**Abbreviations:** Andersen-Tawil syndrome (ATS)

**Running title**: ATS with heart block

# Introduction

Andersen-Tawil syndrome (ATS) is a rare autosomal dominant neuromuscular disorder due to mutations in the KCNJ2 gene that codes for the inwardly rectifying potassium channel Kir2.1(1). This channel is expressed in both cardiac and skeletal muscle as well as some bony structures. The characteristic phenotype of ATS is a triad of periodic muscle paralysis, dysmorphic features and cardiac rhythm abnormalities related to QT prolongation (1). Cardiac or neuromuscular symptoms may dominate the clinical picture in any individual however dysmorphic features may be subtle, making a unifying diagnosis challenging. Cardiac involvement varies, ranging from asymptomatic individuals with an incidentally noted abnormal electrocardiogram to reports of sudden cardiac death, usually attributed to ventricular tachyarrhythmias (2). Advanced atrioventricular (AV) block has not been previously reported in ATS.

**Case Report**

A 57 year old gentleman was referred to the UK National referral centre for neuromuscular channelopathies with symptoms of episodic weakness. Early history and development were unremarkable. In his teens he began to complain of episodes of “mild” weakness predominantly affecting the legs e.g. walking home from school was difficult but he was still able to mobilise. These episodes persisted throughout life but were not investigated. In his early 50’s he complained of an increase in these symptoms but also new episodic breathlessness, fatigue and pre-syncope. Witnesses described him as looking “ashen” during these.

During a severe event he was admitted to hospital. Complete AV block was diagnosed (Fig 1A), and a pacemaker was implanted. Coronary angiography demonstrated no significant coronary artery disease. His symptoms of dizziness ceased but one year later he represented complaining of increasing intermittent limb weakness with fatigue, occurring every few weeks. Episodes were often provoked by exercise or cold weather and could last from hours to several days.

His pacemaker was interrogated and showed no arrhythmias. An echocardiogram confirmed a structurally normal heart. He completed a treadmill test after nine minutes, complaining of fatigue and dizziness with normal chronotropic response being documented. A tilt-table test showed a normal blood pressure response.

Following the exclusion of a cardiac cause of his symptoms he was investigated extensively at his local neurology centre with normal brain imaging, MR intracranial angiogram and EEG.

When referred to our centre micrognathia was noted (Fig1B) but the remainder of the examination was normal. Given the description of episodic muscle weakness, the micrognathia and history of cardiac disease he was investigated for the possibility of ATS. An EMG with long-exercise test (LET) was within normal limits. Genetic testing identified a novel heterozygous KCNJ2 variant c.779G>A p. Arg260His.

Two electrode voltage clamp recordings made from xenopus oocytes transfected with human KCNJ2 Arg260His mRNA demonstrated typical loss of function changes seen in ATS variants (Fig 1C). No current was recorded from cells expressing Arg260His alone but when co-expressed with wild-type mRNA reduced currents were detected indicating a dominant negative effect of the Arg260His variant. Another substitution of the same amino acid, Arg260Pro, has been previously reported in association with ATS and functional studies confirmed its pathogenicity (3).

**Discussion**

In a study in 96 patients with ATS, conduction disturbances were found in 23% of cases, including 1st degree atrioventricular block, right bundle branch block, left bundle branch block and non-specific intraventricular conduction delay (4). Cardiomyocytes expressing a dominant-negative subunit of Kir2.1 exhibited a 95% reduction in the inward rectifying potassium current, resulting in significant action potential prolongation. Mouse models of Andersen-Tawil syndrome exhibited a slower heart rate and significant slowing of conduction (5, 6). Therefore it is likely that the complete AV block in our case is attributable to the *KCNJ2* variant.

Our report illustrates factors that can delay the diagnosis of ATS but are important for clinicians to be aware of, namely that dysmorphic features can be minimal; either cardiac or muscle symptoms may dominate the clinical picture and a negative long exercise test does not exclude the diagnosis of ATS. A negative LET has been reported in 18% of genetically confirmed patients in one series (7) and recurrent muscle weakness in only 35% of another series presenting predominantly with cardiac complaints (2). Complete heart block has not previously been described in ATS meaning it may not be considered in the differential diagnosis of patients presenting with unexplained AV block. Additionally, patients with ATS often receive b-blockers as treatment for QT prolongation and the possible propensity for advanced conduction disease needs to be taken into account in decision making. Sudden cardiac death or aborted cardiac death has been described in ATS patients, mainly driven by ventricular arrhythmias (2). It is possible however that some cases of unexplained sudden cardiac death may have been due to high degree atrioventricular block rather than tachyarrhythmia. This has important implications for both the diagnosis and cardiac management of ATS patients.

**Study funding and disclosures**

Part of this work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.

Dr Suetterlin is supported by an MRC Clinical Research Training Fellowship (MR/M01827X/1). Dr Matthews is supported by a Wellcome Clinical Research Career Development Fellowship (209583/Z/17/Z). Prof Hanna is supported by the UCLH Biomedical Research Centre, and the National Highly Specialised Service (HSS) Department of Health UK. The authors report no other disclosures.

**Patient consent:** The patient signed a written informed consent stating that data can be used for research and education, approved by The Joint National Hospital for Neurology and Institure of Neurology Research ethics Committee.

Reference List

(1) Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. *Ann Neurol* 1994 Mar;35:326-330.

(2) Mazzanti A, Guz D, Trancuccio A, et al. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. *J Am Coll Cardiol.* 2020 Apr 21;75(15):1772-1784

(3) Barajas-Martinez H, Hu D, Ontiveros G, et al. Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. *Circ Cardiovasc Genet* 2011 Feb;4:51-57.

(4) Zhang L, Benson DW, Tristani-Firouzi M, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. *Circulation* 2005 May 31;111:2720-2726.

(5) Zaritsky JJ, Redell JB, Tempel BL, Schwarz TL. The consequences of disrupting cardiac inwardly rectifying K(+) current (I(K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. *J Physiol* 2001 Jun 15;533:697-710.


(6) McLerie M, Lopatin AN. Dominant-negative suppression of I(K1) in the mouse heart leads to altered cardiac excitability. *J Mol Cell Cardiol* 2003 Apr;35:367-378.

(7) Tan SV, Matthews E, Barber M, et al. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. *Ann Neurol* 2011 Feb;69:328-340.


**B**



**A**



**C**



**Fig 1: A:** ECG showing complete heart block pre-pacemaker insertion **B:** Facial characteristics of our patient demonstrating micrognathia **C:** Oocytes injected with WT Kir2.1 RNA (squares, n=24), R260H Kir2.1 RNA (solid circles, n=20) or 1:1 mixture of these (open circles, n=26)were held at 0 mV and then clamped to test voltages ranging from -150 mV to 50 mV in 10 mV increments. Current at the beginning of the voltage step was measured. The local conductance (slope of the current–voltage relationship for each 10-mV voltage increment) is plotted against the voltage and shown as mean ± standard error. Data for uninjected cells is shown as filled hexagons with grey shade. The data show that cells expressing R260H channels carried no currents. The conductance at -100 mV in cells expressing WT and R260H channels was ~1/3 of that recorded in cells expressing WT channels (p<0.001) implicating dominant negative effects. Recordings were done in 120 mM extracellular K+.